OSX's Principal Activity is the medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. It also fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-1.44%|
|vs ASX 200 (1yr)||-34.63%|
|ASX Rank||1,402 of 2,249|
|Sector Rank||122 of 177|
Osteopore Limited (OSX) is an Australian and Singapore based medical technology company commercialising a range of products engineered to facilitate bone healing across range of therapeutic areas. The Group's patented technology fabricates micro-structured scaffolds for bone regeneration through 3D printing & bioresorbable material, bioresorbable scaffolds for regenerative bone healing.
No incorporation details available.
|No dividends paid.|
See Upcoming Dividends for all ASX companies.
|Mr Stuart John Carmichael||Non-Executive Director||Dec 2019||
Mr Stuart John Carmichael
Mr Carmichael have 20 years of experience in the provision of corporate advisory services both within Australia and internationally. Mr Carmichael is a partner and director of Ventnor Capital Pty Ltd and Ventnor Securities Pty Ltd which specialises in the provision of corporate and financial advice to small cap ASX listed companies including capital raisings, initial public offerings, corporate restructures and mergers and acquisitions.
|Mr Brett Sandercock||Non-Executive Chairman,Non-Executive Director||Jun 2019||
Mr Brett Sandercock
Non-Executive Chairman,Non-Executive Director
Mr Sandercock was appointed Chief Financial Officer of Resmed Limited (NYSE: RMD, ASX: RMD) in January 2006. Previously he served as Resmed's Vice President of Treasury and Finance from November 2004 until December 2005, and group accountant and controller from 1998 to 2004 Before joining ResMed, Mr Sandercock was Manager of Financial Accounting and Group Reporting at Norton Abrasives from 1996 to 1998. He also held finance and accounting roles from 1994 to 1996 at Health Care of Australia. From 1989 to 1994, he worked at PriceWaterhouse Coopers in Sydney, specialising in audits of clients across distribution and manufacturing financial services, technology, and other industries.
|Mr Geoffrey (Geoff) Richard Pocock||Executive Director||Jun 2019||
Mr Geoffrey (Geoff) Richard Pocock
Mr Pocock has experience as a corporate advisor and strategy consultant advising companies on commercialisation and IP management, business development, mergers and acquisitions strategy and raising equity capital from private and public equity markets. Mr Pocock is currently the Principal of Polaris Consulting (WA) Pty Ltd, and was formerly the Managing Director of Hazer Group Ltd, an ASX-listed cleantech chemical engineering company, commercialising a novel low cost and low emission graphite and hydrogen production process initially developed by the University of Western Australia. Mr Pocock previously spent several years as a research scientist in the biopharmaceutical industry in Australia and the United Kingdom.
|Professor Swee Hin Teoh||Non-Executive Director||Jun 2019||
Professor Swee Hin Teoh
Prof Teoh is the President's Chair, School of Chemical and Biomedical Engineering (SCBE). He holds a joint appointment with the Lee Kong Chian School of Medicine (LKC Med) at Nanyang Technological University. His contribution is in the development and clinical translation of 3D bioresorbable scaffolds. Majoring in Materials Engineering (B. Eng - 1st Class Hon and PhD, Monash University), his research journey focused on translating the materials research to biomedical benefits. He is a Fellow of the Academy of Engineers Singapore and Chief Engineer at Skin Research Institute of Singapore. His research focused on the study of mechanisms that promote cells proliferation and differentiation as a result of mechno induction through load bearing scaffolds for tissue regeneration and remodelling. Prof. Teoh's work on 3D printed scaffold led to him receiving the prestigious "Golden Innovation Award" at the Far East Economic Review, and the Institute of Engineers "Prestigious Engineering Achievement Award" in 2004. His group was ranked 1st in bone tissue engineering scaffolds in World Web of Science 2010. He was honoured with the Special Award for "Scientific Life-Time Achievement in Bone Tissue Engineering" at Bone-Tec 2015, Stuttgart. As a part of SG50 celebrations, he was featured as one of Singapore's profiled scientists in the book titled Singapore's Scientific Pioneers. Prof. Teoh is presently the Chairman, Singapore Academy, Asia Regulatory Professional Association (ARPA). He sits in as board of editors Tissue Engineering, Journal of Tissue Engineering and Regenerative Medicine, Journal of Mechanical Behaviour of Biomedical Materials, Journal of Oral & Maxillofacial Research and Proceedings of the Institution of Mechanical Engineers Part H: Journal of Engineering in Medicine.
|Mr Khoon Seng Goh||Chief Executive Officer||Sep 2018||
Mr Khoon Seng Goh
Chief Executive Officer
Mr Goh has 30-year career spans both start-ups and global multinational corporations, with responsibilities in research and development, manufacturing, regional sales and marketing, and country management. Prior to joining Osteopore Mr Goh spent over 20 years with Medtronic plc (Medtronic plc is the world's largest medical device company) and Edwards Lifesciences Asia in various senior management roles. Mr Goh has been a Director of Osteopore Pte Ltd, since 2015 and has been involved in all aspects of the Company.
|Ms Deborah Ho||Company Secretary||N/A|
|Carl Runde||Chief Financial Officer||N/A|
|Lim Jing||Chief Technology Officer||N/A|
The current holdings of OSX directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
|Swee Hin Teoh||31/12/2020||7,030,309||N/A||1,500,000||N/A|
|Geoffrey (Geoff) Pocock||31/12/2020||N/A||168,539||1,200,000||N/A|
|Khoon Seng Goh||N/A||N/A||N/A||N/A||N/A|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
|Name||Last Notice||Total Shares||Shares Held (%)|
|The Rain Maker MGMT Pte Ltd||23/02/2021||9,285,927||7.92|
|Goh Khoon Seng||23/02/2021||6,835,316||5.83|
|Teoh Swee Hin||23/02/2021||7,030,309||6.00|
12 month transaction history compiled from ASX announcements.
No buy transactions reported by Substantial Shareholders in the past 12 months.
12 month transaction history compiled from ASX announcements.
|Date||Name||Sold||Previous %||New %|
|16-12-20||The Rain Maker MGMT SDN BHD||1,985,000||15.1||11.3|
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.